MoneyWorks4Me

Biocon informs about company statement

08 Sep 2021 Evaluate

Biocon has informed that the company and its subsidiaries Biocon Pharma \ and Biocon Pharma Inc. (‘Biocon’) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide).” The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..